Kim SJ. Role of muscular eNOS in skeletal arteries: endothelium-independent hypoxic vasoconstriction of the femoral artery is impaired in eNOS-deficient mice. Am J Physiol Cell Physiol 311: C508 -C517, 2016. First published July 27, 2016; doi:10.1152/ajpcell.00061.2016.-We previously reported that hypoxia augments ␣-adrenergic contraction (hypoxic vasoconstriction, HVC) of skeletal arteries in rats. The underlying mechanism may involve hypoxic inhibition of endothelial nitric oxide synthase (eNOS) expressed in skeletal arterial myocytes (16). To further explore the novel role of muscular eNOS in the skeletal artery, we compared HVC in femoral arteries (FAs) from eNOS knockout (KO) mice with that from wild-type (WT) and heterozygous (HZ) mice. Immunohistochemical assays revealed that, in addition to endothelia, eNOS is also expressed in the medial layer of FAs, albeit at a much lower level. However, the medial eNOS signal was not evident in HZ FAs, despite strong expression in the endothelium; similar observations were made in WT carotid arteries (CAs). The amplitude of contraction induced by 1 M phenylephrine (PhE) was greater in HZ than in WT FAs. Hypoxia (3% PO 2) significantly augmented PhE-induced contraction in WT FAs but not in HZ or KO FAs. No HVC was observed in PhE-pretreated WT CAs. The NOS inhibitor nitro-L-arginine methyl ester (0.1 mM) also augmented PhE contraction in endothelium-denuded WT FAs but not in WT CAs. Inhibitors specific to neuronal NOS and inducible NOS did not augment PhE-induced contraction of WT FAs. NADPH oxidase 4 (NOX4) inhibitor (GKT137831, 5 M), but not NOX2 inhibitor (apocynin, 100 M), suppressed HVC. Consistent with the role of reactive oxygen species (ROS), HVC was also inhibited by pretreatment with tiron or polyethylene glycol-catalase. Taken together, these data suggest that the eNOS expressed in smooth muscle cells in FAs attenuates ␣-adrenergic vasoconstriction; this suppression is alleviated under hypoxia, which potentiates vasoconstriction in a NOX4/ ROS-dependent mechanism. endothelial nitric oxide synthase; smooth muscle; skeletal artery; hypoxic vasoconstriction NITRIC OXIDE SYNTHASES (NOS) expressed in endothelium [endothelial NOS (eNOS), NOS3] exert a vasorelaxing effect. Various stimulations of the endothelium activate eNOS via Ca 2ϩ /calmodulin (CaM)-dependent signaling pathways and/or phosphorylation of eNOS. Activated eNOS converts L-arginine and O 2 to L-citrulline and NO, using NADPH as a reducing substrate. The released NO diffuses into the smooth muscle cells and subsequently activates soluble guanylate cyclase (sGC), which produces cGMP to induce vasodilation. In the field of vascular physiology, it is widely believed that physiological eNOS expression is localized to the endothelium and that smooth muscle cells are passively regulated by released NO, a major endothelium-derived relaxing factor (12, 28). However, studies using molecular biological techniques (4, 5) and functional assays in endothelium-denuded arterial rings from aortic, mesenteric, and pulmonary arteries (3) provide intriguing evidence that eNOS is also expressed in vascular smooth muscle cells (VSMCs).
(sGC), which produces cGMP to induce vasodilation. In the field of vascular physiology, it is widely believed that physiological eNOS expression is localized to the endothelium and that smooth muscle cells are passively regulated by released NO, a major endothelium-derived relaxing factor (12, 28) . However, studies using molecular biological techniques (4, 5) and functional assays in endothelium-denuded arterial rings from aortic, mesenteric, and pulmonary arteries (3) provide intriguing evidence that eNOS is also expressed in vascular smooth muscle cells (VSMCs).
We recently reported hypoxic vasoconstriction (HVC) in rat skeletal arteries, which may be mediated by hypoxic inhibition of eNOS in VSMCs. In deep femoral arteries (DFAs) of rats, partial contraction induced by submicromolar phenylephrine (PhE) is dramatically enhanced by hypoxia (3% PO 2 ) , and this effect is mimicked by nitro-L-arginine methyl ester (L-NAME). HVC can also occur in the absence of functional endothelium. In addition, immunohistochemistry and RT-PCR analyses suggested that eNOS is expressed in VSMCs of rat DFAs. On the basis of these results, we proposed that NO produced by muscular eNOS in skeletal arteries could attenuate vasoactive agonist-induced contraction in an autocrine manner (16) . Regarding the physiological implications of HVC, we proposed that hypoxemia in association with increased sympathetic tone might augment the peripheral resistance of skeletal vessels to maintain blood pressure and ensure perfusion of vital organs, such as brain and heart. Although molecular biological and pharmacological studies suggest a physiological role of eNOS expressed in VSMCs, direct evidence obtained using genetically nullified vessels has not been published to date. In this study, using knockout (eNOS Ϫ/Ϫ , KO) mice, we investigated whether HVC is actually impaired in the mouse skeletal artery. To this end, we monitored the presence of HVC and performed immunohistochemical analyses in the femoral arteries (FAs) from the wild-type (WT) and compared the results with those from heterozygous (eNOS ϩ/Ϫ , HZ) and KO mice. In addition, to get a clue for the mechanism of HVC, we tested the effects of NADPH oxidase (NOX) inhibitors and reactive oxygen species (ROS) scavenger.
MATERIALS AND METHODS

Animals. Breeding pairs of eNOS
ϩ/Ϫ , HZ mice (stock no. 002684), were purchased from Jackson Laboratory (Bar Harbor, ME). To generate eNOS Ϫ/Ϫ , KO mice and HZ mice were bred with each other. Genotyping of HZ and KO was performed by a PCR method using genomic DNA prepared from tail biopsies. All experiments were performed using 21-to 25-wk-old male mice. They were taken care of with strict compliance to the Guidelines for Care and Use of Laboratory Animals issued by the Institutional Animal Care and Use Committee (IACUC) of Seoul National University (IACUC approval number: SNU-141029-5, Korea) according to the guidelines from the Guide for the Care and Use of Laboratory Animals of the NIH. Mice were housed under specific pathogen-free conditions and standard conditions of room temperature, humidity (40 -60%) and a 12-h:12-h light/dark cycle.
Isometric tension measurement. Mice were anesthetized (60 mg/kg pentobarbital sodium) and quickly killed by cervical dislocation, and their proximal hind limbs were dissected in cold normal Tyrode's (NT) solution for the isolation of FAs. In some mice, mesenteric arteries (MAs) and carotid arteries (CAs) were also dissected to be compared with FAs. The NT solution for dissection contained (in mmol/l): 140.00 NaCl, 5.40 KCl, 0.33 NaH 2PO4, 10.00 HEPES, 10.00 glucose, 1.00 CaCl2, and 1.00 MgCl2, pH 7.4 titrated with NaOH.
The segment of arteries was mounted on 25-m wires in a dualwire myograph system (620 M; DMT, Aarhus, Denmark) and stabilized in physiological salt solution (PSS) equilibrated with 21% O 2-5% CO2 and N2 balanced at 37°C. The length of FA ring segment was kept constant (ca. 3 mm). The PSS to measure arterial tension contained (in mmol/l): 118.00 NaCl, 4.00 KCl, 0.44 NaH2PO4, 24.00 NaHCO3, 1.80 CaCl2, 1.00 MgSO4, and 5.60 glucose. To confirm the viability of arteries as well as to obtain a standard contraction, the response to 80 mM KCl-PSS (80K) was measured initially. In each vessel, endothelium-dependent relaxation (EDR) was evaluated by applying 10 M acetylcholine (ACh) in the presence of 10 M PhE. For exposure to the hypoxic condition, the gas was changed to 3% O 2-5% CO2 balanced with N2.
Immunohistochemistry. Dissected arteries were fixed in 4% paraformaldehyde at 4°C for 1 day. Tissues were washed, paraffin embedded, and cut into sections. With the use of the Discovery XT automates immunohistochemistry stainer (Ventana Medical System, Fig. 1 . Immunohistochemistry of endothelial nitric oxide synthase (eNOS) expression. Representative images in wild-type (WT) (A), heterozygous (HZ) (B), and knockout (KO) (C) femoral arteries (FAs) were obtained from 3 different mice, respectively. Whereas the intima of WT and HZ FAs showed prominent positive signal of eNOS expression, the media of WT showed more brownish stain than those of HZ and KO FAs. Images of mouse mesenteric artery (D) and carotid artery (CA) (E) commonly showed prominent eNOS signal in the intima while not in the media. All images were taken at ϫ40; scale bar ϭ 50 m.
Tucson, AZ), slides were stained as follows: sections were deparaffinized using EZ Prep solution. CC1 standard (pH 8.4 buffer containing Tris/borate/EDTA) was used for antigen retrieval. Inhibitor D was blocked for 4 min at 37°C. Slides were incubated with primary eNOS antibody (1:500 dilution used; BD Bioscience, San Jose, CA) for 32 min at 37°C and a secondary antibody of anti-mouse with Dako Envisionϩ system horseradish peroxidase (Dako, Glostrup, Denmark) for 20 min at 37°C. Slides were incubated in diaminobenzidine ϩ H2O2 substrate for 8 min at 37°C followed by hematoxylin and bluing reagent counterstain at 37°C.
Drugs and chemicals. All drugs and chemicals used in this study were obtained from Sigma (St. Louis, MO).
Statistical analysis. Data were given as original traces and means Ϯ SE, and n indicated the number of tested arteries. Mean values were compared using Student's unpaired or paired t-test. The value of P Ͻ 0.05 was considered significant. Significance values were *P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001.
RESULTS
Immunohistochemistry of WT mice suggested that eNOS is expressed in smooth muscle cells of FAs and more prominently expressed in the endothelium. The medial layer of FAs exhibited diffuse and punctate positive signals for eNOS (Fig. 1A) . By contrast, in HZ FAs, we observed relatively strong eNOS signals in endothelium but negligible staining in the medial layer (Fig. 1B) . In KO FAs, as predicted, eNOS signals were almost absent in both layers (Fig. 1C) . In other systemic arteries, such as MAs and CAs, eNOS was strongly expressed in endothelia while not evident in the medial layer (Fig. 1, D 
and E).
To verify the contractility of tested vessels, we compared the amplitudes of 80 mM potassium solution (80K) contractile force between WT, HZ, and KO FAs. In 25/45 KO FAs tested for 80K contraction, the contractility appeared too small to proceed with HVC and other procedures. Thus KO FAs showing Ͻ0.5 g force of the 80K condition were not included for further analysis. Nevertheless, the 80K contractions in KO FAs were generally smaller than those in WT and HZ FAs ( Fig.  2A) . KO FAs also exhibited weaker responses to angiotensin II (Ang II, 1 M) and ionomycin (10 M) than WT and HZ FAs. Interestingly, the amplitudes of Ang II-and ionomycin-induced contractions in HZ FAs were greater than those in WT FAs (Fig. 2B , *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001).
To compare the sensitivities of FAs to ␣-adrenergic stimuli between the groups, amplitudes of contractions induced by PhE (0.05-10.00 M) were normalized against those of the 80K contraction in each vessel, and the summarized values were plotted (Fig. 2, C and D) . When the functional endothelium was impaired by mechanical rubbing (EDR Ͻ30% of the contraction induced by 10.0 M PhE), the contractions induced by 0.5, 1.0, 2.0, 5.0, and 10.0 M PhE were much larger in HZ FAs than in WT or KO FAs (Fig. 2C ). Because the EDR of KO FAs was intrinsically impaired, we compared data from KO FAs with those obtained from endothelium-denuded vessels. The normalized sensitivity to PhE was higher in KO than WT at lower concentrations of PhE (Ͻ1 M, Fig. 2C ) although this difference was not statistically significant. When the endothelium was preserved in WT and HZ (i.e., mechanical rubbing was not performed), the levels of EDR did not differ C: comparison of the concentration-dependent contractile responses to phenylephrine (PhE) between WT (), HZ (), and KO (OE) FAs. In each vessel, the PhE contractions were normalized to the 80K contraction. In WT and HZ FAs, endothelia were removed by mechanical abrasion. D: contractile responses to PhE in the endothelium-intact WT () and HZ () FAs. *P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001. significantly between WT and HZ: 72.20 Ϯ 3.63% and 61.40 Ϯ 6.90%, respectively, relative to the contractions induced by 10 M PhE. Nevertheless, the normalized PhEinduced contraction was still stronger in HZ than in WT FAs (Fig. 2D , **P Ͻ 0.01). These results suggest that, like endothelium-dependent relaxing signals, nonendothelial (i.e., muscular) eNOS might also attenuate contractile responses to ␣-adrenergic stimulation of the FA.
After confirming 80K contraction and EDR in FAs from WT mice, we analyzed the response to hypoxia (3% PO 2 ). Hypoxia alone had no effect on the basal tone of FAs (Fig. 3A) . By contrast, PhE-induced partial contraction (25-30% of the 80K contraction) was significantly augmented by combined hypoxia (Fig. 3B) . The hypoxia-induced sustained and reversible contraction (HVC) was comparable to the 80K contraction. Also the HVC was similar regardless of the level of EDR (Fig.  3, B and C) . Because the level of contraction induced by PhE was higher in the endothelium-denuded than endotheliumintact FAs, 0.5 and 1.0 M PhE were applied to each group, respectively. The statistical analyses of normalized PhE contraction and the effects of hypoxia were separately performed (Fig. 3D) . In subsequent experiments comparing the responses of endothelium-denuded and -intact arteries, different concentrations of PhE were applied to induce precontraction.
As with HVC, pharmacological inhibition of eNOS by 100 M L-NAME augmented the PhE-induced contraction in WT FAs, irrespective of the EDR level (Fig. 4) . Treatment with L-NAME alone did not affect the basal tone of WT FAs (data not shown). In addition, we tested whether PhE-induced contraction of FAs would be affected by an inducible NOSspecific inhibitor, N- [3-(aminomethyl) benzyl] acetamidine (1400W, 5 M) (14), or by a neuronal NOS-specific inhibitor, S-methyl-L-thiocitrulline (SMTC, 100 nM) (13) . Neither 1400W nor SMTC treatment augmented PhE-induced contraction. In addition, we consistently observed HVC in the presence of both inhibitors (Fig. 5) .
In HZ FAs not subjected to mechanical rubbing of the endothelium, ACh-induced EDR was similar to that of WT FAs (61.44 Ϯ 6.90% of 10 M PhE contraction, n ϭ 12). However, no HVC was observed following pretreatment with PhE, irrespective of the EDR (Fig. 6, A, B, and D) . In addition, KO FAs did not exhibit any HVC in the presence of PhE (Fig.  6, C and D) . A slight relaxation was sometimes induced by 10 M ACh in KO FAs, suggesting the presence of eNOSindependent EDR (Fig. 6C) .
In HZ FAs with relatively preserved endothelium (EDR Ͼ30%), application of L-NAME to PhE-pretreated vessels induced a slight additional contraction (Fig. 7, A and D) . However, in endothelium-denuded HZ FAs, no further contraction was observed in response to L-NAME (Fig. 7, B and  D) . KO FAs also failed to respond to L-NAME under PhE pretone (Fig. 7, C and D) . In contrast to FAs, endotheliumdenuded CAs from WT mice exhibited neither HVC-nor L-NAME-induced contraction under pretone by 0.5-1.0 M PhE (Fig. 8, A and B) .
In the previous study of rat skeletal artery, we suggested that NOX4 plays a role in the HVC based on the mimicking effects of plumbagin, a naphthoquinone-derived agent, and a nonspecific oxidase inhibitor, diphenyleneiodonium (16) . To get a clue for the mechanism of HVC in the mouse FAs, here we tested with a specific NOX4 inhibitor, GKT137831 (15) . In- terestingly, the HVC of mouse FAs was abolished by the pretreatment with 5 M GKT137831 (Fig. 9A) . In contrast, the NOX2 inhibitor apocynin did not affect HVC (Fig. 9B) . To further prove the role of ROS, a ROS scavenger tiron (1 mM) or polyethylene glycol (PEG)-catalase (352 U/ml) was applied. Both agents showed inhibitory effects on the HVC of mouse FAs (Fig. 9, E-G) . It is also notable that the treatment of tiron elicited partial relaxation of the PhE constriction (Fig. 9, G and H) .
DISCUSSION
The results of this study provide evidence that mouse FAs also exhibit HVC in the presence of ␣-adrenergic agonist. This effect was absent in FAs from HZ and KO mice but was consistently observed in EDR-impaired WT FAs. The augmentation of contraction in PhE-pretreated FAs by L-NAME, but not by 1400W or SMTC, as well as the results of immunohistochemistry indicated that eNOS is expressed and functionally important in the smooth muscle layer of FAs. Taken together, our findings suggest that muscular eNOS and its inhibition under hypoxia combined with ␣-adrenergic stimulation are responsible for the HVC of skeletal arteries in mice. Also, the ROS produced by NOX4 might play a role in the HVC although its precise mechanism is still unclear (Fig. 10) .
In addition to the absence of HVC in KO mice, HZ FAs failed to undergo HVC despite preserved EDR (Fig. 6) . Given that HZ siblings are often used as controls for investigations of KO mice, the discrepancy in the HVC responses between WT and HZ FAs drew our attention. The intact EDR in HZ FAs was consistent with the immunohistochemical findings of positive eNOS signal in the endothelial layer. However, the immunohistochemical signal for eNOS in the medial layer differed significantly between WT and HZ FAs (Fig. 1, A and  B) . In addition, the L-NAME-induced contraction in the presence of 0.5-1.0 M PhE was abolished in HZ FAs irrespective of the EDR level. We conclude that the reduced level of eNOS in HZ FAs significantly attenuated the functional contribution of muscular eNOS to anticontractile signaling. Because it is expressed at relatively high levels in the endothelium, a partial decrease in the contribution from the eNOS (i.e., EDR) might be undetectable in HZ FAs. However, more rigorous investigation of EDR might have detected a difference between WT and HZ FAs. An early study of eNOS-deficient mice revealed a decrease in maximum EDR in HZ mice (11) .
Our results also revealed higher sensitivity to PhE in HZ than in WT FAs (Fig. 2, C and D) . This higher sensitivity to sympathetic stimuli might underlie the systemic hypertension observed in eNOS HZ mice (10) . Not only PhE, but also Ang II and ionomycin, induced higher contractile responses in HZ than WT FAs (Fig. 2B ). Although such results suggest that a partial decrease in eNOS expression might have augmented the contractility, the unchanged level of 80K contraction was an inconsistent finding ( Fig. 2A) . Functional analysis of the voltage-gated Ca 2ϩ channel current is required to address the differential responses to 80K and agonists in HZ FAs.
Previous studies of eNOS KO mice revealed a hypertensive phenotype, indicating a role for basal eNOS activity in regulation of vascular tone (25, 34, 35) and a less hyperpolarized membrane potential of arterial smooth muscle (7) . In this study, however, we observed that KO FAs exhibited significantly weaker contractility, which is not described in the previous literature. We cannot yet explain the reduced contractility in KO FAs. Endothelial NO production is also required for other aspects of vessel functions and integrity (20) . Therefore, in the context of long-term genetic deficiency, the lack of muscular eNOS in the FA might somehow affect the contractility of the cardiovascular system. eNOS expression in vascular smooth muscle. Only a few studies have reported immunohistochemical and molecular biological evidence for the expression of eNOS in VSMCs (4, 5, 16) . Because both contractile signals and eNOS activation require Ca 2ϩ /CaM signaling, eNOS in VSMCs may serve as an intrinsic counterbalance. We recently showed that mechanical stretching of the pulmonary arterial wall facilitates muscular eNOS activation, which would lower the resistance of pulmonary circulation induced by intrinsic contractile signals from thromboxane A 2 and mechanical stimuli (24) . Thus the physiological role of eNOS in vascular smooth muscle is not limited to skeletal arteries.
Several reports suggest that the medial cells of bovine CAs, human renal arteries (4), and rat aorta (5) can generate NO, which might modulate vascular functions in an endotheliumindependent manner (2, 37). However, in this study, we observed neither HVC nor L-NAME-induced contraction in mouse CAs. In our hands, functionally significant expression of eNOS in VSMCs seems to be restricted to specific types of vessels, such as skeletal and pulmonary arteries (24) . Experimental damage (e.g., mechanical abrasion) of the endothelial layer evokes production of ROS, which convert myogenic NO into nonfunctional forms. Such experimental artifacts might have concealed the functional role of muscular eNOS in endothelium-denuded vessels tested by other researchers (3). Questions on the signaling mechanisms of HVC. On the basis of the differential responses of WT, HZ, and KO FAs to hypoxia, we hypothesize that HVC in skeletal arteries is mediated by hypoxic inhibition of muscular eNOS. Although the effects of GKT137831, tiron, and PEG-catalase suggested the roles of NOX4 and ROS, we cannot provide a clear explanation of the signaling mechanism for eNOS inhibition under hypoxia. A cautious assumption is that hypoxia might directly suppress eNOS in a reversible manner because O 2 is a critical substrate for the enzymatic function of eNOS. Consistent with this idea, EDR in pulmonary and basilar arteries is inhibited by hypoxia (9, 22, 30, 31) . Alternatively, other modulatory signals, such as eNOS phosphorylation, might be activated by hypoxia in combination with vasoactive agonists. According to previous reports, hypoxia induces phosphorylation of eNOS at Thr495, which is involved in inhibitory modulation of its NOS activity (19, 21, 29) . Because of the limited number of tissue samples available for our analysis of eNOS expression in FA myocytes, we could not perform a direct investigation of eNOS phosphorylation or translocation in cells.
Our results also show critical roles of ROS and H 2 O 2 that appear to be generated by NOX4 according to the effects of pharmacological inhibitors (Fig. 9) . Vascular NOX4 has been suggested to provide endogenous H 2 O 2 that positively affects a variety of vascular functions, especially under pathological conditions. The vasoprotective roles of NOX4 could include angiogenesis, heme oxygenase-1 expression, and eNOS expression under ischemia-induced angiogenesis and angiotensin II-induced vascular dysfunction (33) . Then what is the role of intrinsic ROS and H 2 O 2 in the HVC of FAs? One hypothesis is that the hypoxic inhibition of eNOS requires NOX4 as a kind of sensor for PO 2 change (Fig. 10A) . The ROS-dependent acute regulation of eNOS is reported to be facilitating, not inhibitory (6) . Thus a decreased ROS production by NOX4 under hypoxia might contribute to the eNOS inhibition. However, the putative decrease of ROS production by NOX4 under hypoxia is not consistent with the common inhibitory effects of catalase, tiron, and GKT137831 on HVC of FAs. Another plausible model is that H 2 O 2 endogenously produced by NOX4 might facilitate the PhE-induced contraction that is revealed by the hypoxic inhibition of eNOS (Fig. 10B) . In fact, the role of agonist-induced H 2 O 2 in the myogenic response of skeletal veins has been reported in skeletal veins (8) . Consistent with this model, an application of tiron, a potent ROS scavenger, partly decreased the amplitudes of PhE contraction (Fig. 9, G  and H) . However, it has to be admitted that the present data do not yet provide a clear answer to the signaling mechanisms of NOX4 and H 2 O 2 for HVC, and further investigation is required to elucidate the signaling mechanisms of HVC.
As discussed above, the use of eNOS KO as an experimental model has revealed general attenuation of vascular responses. Because the eNOS signaling is involved in many aspects of cell function, expressions of many other proteins could be altered in the eNOS KO mice. Although the present study provides pharmacological and immunohistochemical evidence along with the genetically modified conditions, careful interpretation is required.
Physiological implications. Our results suggest that eNOS expressed in VSMCs of skeletal arteries might play a physiological role under specific conditions, such as hypoxia/hypoxemia. Hypoxemia is encountered at high altitudes and in patients with respiratory insufficiency. The response of skeletal arteries to hypoxemia varies depending on the species investigated and the severity of hypoxemia (17, 18, 26) . In studies of rats, severe hypoxemia (6%) elicited constriction of arterioles in vivo (27) . In healthy humans, mild or severe acute hypoxemia causes diverse changes, including reduced leg blood flow (1) . Because of the relatively large capacity of skeletal vessels, especially during exercise, perfusion of contracting muscles must be finely regulated. Under sympathetic stimulation, large vessels undergo vasoconstriction, whereas constriction in smaller vessels is blunted, resulting in optimal distribution of total muscle blood flow (32) . Sympathetic activation may increase under stress, such as severe hypoxemia, via chemoreceptors such as the carotid body (23 An acute exposure to hypoxia inhibits the eNOS-NO pathway, which depends on the signals from NOX4 such as H2O2. The elimination of relaxing influence from the muscular eNOS augments the net contraction of the skeletal arteries (right). B: contractile response to PhE is facilitated by ROS, including H2O2 generated by NOX4, which is partly attenuated by concomitant activation of eNOS (left). Under hypoxia, inhibition of myogenic eNOS reveals the strong contraction (right). muscle mass involved in whole body activity, the magnitude of sympathetic restraint to muscle blood flow should be higher under hypoxia than normoxia (36) . Thus the HVC responses observed in skeletal feeding arteries (e.g., FAs) might contribute to systemic regulatory mechanisms in vivo. 
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